2013
DOI: 10.1002/9780470151808.sc02d14s24
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Proliferation of Neural Stem Cells In Vitro and In Vivo

Abstract: This unit describes two basic protocols for the detection of the proliferation of neural stem cells (NSC). The first one addresses cell proliferation in cultures, starting with primary cell cultures isolated from the mouse subventricular zone (SVZ), in which SVZ‐derived NSC are kept in culture as neurospheres. By using this culture system, we are able to study different stages of adult neurogenesis, such as proliferation, differentiation, migration, and survival. Thus, in the first basic protocol, we describe … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 63 publications
(82 reference statements)
0
9
0
Order By: Relevance
“…Almost a decade ago, FNC of bromodeoxyuridine (BrdU) labeled mouse hippocampal nuclei was used to demonstrate the ability of therapeutics (e.g., imipramine) to double cell proliferation rates (Bilsland et al, 2006). However, BrdU labeling has its limitations and may be a better predictor of DNA repair, underestimating both the number of cells undergoing normal DNA replication based cell proliferation and cells with neurogenic potential (Zheng et al, 2011;Morte et al, 2013). Our work suggests that cell proliferation assays based on the analysis of populations of brain cell nuclei should be revisited as a powerful approach to examine neurodegenerative diseases and therapeutics.…”
Section: Cell-type-specific Analyses Of Disease Models Using Fnc and mentioning
confidence: 99%
“…Almost a decade ago, FNC of bromodeoxyuridine (BrdU) labeled mouse hippocampal nuclei was used to demonstrate the ability of therapeutics (e.g., imipramine) to double cell proliferation rates (Bilsland et al, 2006). However, BrdU labeling has its limitations and may be a better predictor of DNA repair, underestimating both the number of cells undergoing normal DNA replication based cell proliferation and cells with neurogenic potential (Zheng et al, 2011;Morte et al, 2013). Our work suggests that cell proliferation assays based on the analysis of populations of brain cell nuclei should be revisited as a powerful approach to examine neurodegenerative diseases and therapeutics.…”
Section: Cell-type-specific Analyses Of Disease Models Using Fnc and mentioning
confidence: 99%
“…Coronal sections from the hippocampal region were cryosectioned (30 μm thick, in 6-series) using a CryoStar NX50 cryostat (Thermo Fisher Scientific, Waltham, MA, USA) and stored in an antifreeze solution (30% ethylene glycol and 30% glycerol in phosphate buffer), at 4°C. Free-floating brain sections from one of the series were labeled against BrdU, DCX, EdU or EdU/NeuN (neuronal nuclei), as previously described (Morte et al, 2013; Machado et al, 2015). EdU labeling was performed using a commercially available kit (Click-iT ® EdU Alexa Fluor ® 488 HCS Assay, Thermo Fisher Scientific, Waltham, MA, USA).…”
Section: Methodsmentioning
confidence: 99%
“…NSC were isolated from the SVZ of P0-3 Cast +/+ and Cast −/− mice and maintained in culture, as previously described (Morte et al, 2013 ). Dissociated NSC ( n = 3) were plated on coverslips coated with 0.1 mg/ml poly-L-lysine (Sigma Aldrich, St Louis, MO, USA) until 60–70% confluency was reached, and then treated with calpeptin 25 μM (Tocris Bioscience, Bristol, UK) for 6 h (untreated cells were used as controls).…”
Section: Methodsmentioning
confidence: 99%